CSF3 and Axenfeld-Rieger syndrome: Although colony stimulating factors such as Neupogen (G-CSF), Neulasta (pegylated G-CSF), and Leukine (GM-CSF) have been approved by the FDA for H-ARS mitigation in humans (Singh and Seed, 2020), their efficacy may be limited with respect to other ARS and DEARE syndromes (Farese et al., 2019).